<DOC>
	<DOCNO>NCT02397057</DOCNO>
	<brief_summary>This Phase III , double blind , multi-center , randomize , placebo-controlled study . Eligible subject randomize 1:1 ratio receive Injectafer Placebo day 0 5 . All treated subject follow efficacy safety 12 month . The subject 's participation study approximately 1 year Day 0 .</brief_summary>
	<brief_title>Placebo-Controlled Study Investigate Efficacy &amp; Safety Injectafer Treatment RLS</brief_title>
	<detailed_description>This Phase III , double blind , multi-center , randomize , placebo-controlled study . Eligible subject randomize 1:1 ratio receive Injectafer Placebo day 0 5 . All treated subject follow efficacy safety 12 month . Subjects visit clinic Days 0 5 treatment , Days 14 , 42 , 168 , 365 . In clinic visit subject contact remotely Days 84 , 126 , 210 , 252 , 294 , 336 . The subject 's participation study approximately 1 year Day 0 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Male female subject 's ≥18 year age , willing able give inform consent study . 2 . RLS symptoms affirm diagnosis . The IRLS Diagnostic Criteria must meet : 1 . An urge ( distress need ) move legs usually associate painful uncomfortable sensation leg . The urge move may present without uncomfortable sensation . The arm body part may involve addition leg . 2 . The urge move unpleasant sensation worse exclusively present rest inactivity , lie sit . 3 . The urge move unpleasant sensation partially/temporarily relieve walk move leg . 4 . The urge move unpleasant sensation worse even night day occur even night . When symptom severe , worsen night may noticeable must previously present . 3 . Subjects monotherapy RLS . Treatment stable least 8 week prior screen ( See approve RLS Therapies/Regimen Appendix III ) . 4 . A score ≥15 IRLS Rating Scale screen Day 0 prior dose . 5 . Subjects antidepressants sleep medication must stable dose least 6 month . 6 . Subject regular sleep hour 9 pm 9 . 7 . Subjects risk pregnancy must negative pregnancy test baseline practice acceptable form birth control : hysterectomy tubal ligation , otherwise incapable pregnancy , practice follow method contraception least one month prior study entry : hormonal contraceptive , spermicide barrier , intrauterine device , partner sterility . 1 . RLS 2° disease injury . 2 . Disorders require treatment medication use RLS include : peripheral neuropathy neurodegenerative disorder ( i.e . Parkinson 's Disease Dementia ) . 3 . Stage 4 5 CKD , subject dialysis anticipated start dialysis participate study . 4 . Any pain relate ( e.g. , frequent muscle cramp , myalgia , fibromyalgia ) sleep relate disorder ( e.g . sleep apnea , unless stable Continuous Positive Airway Pressure [ CPAP ] ) may confound outcome measure . 5 . Subjects multiple sclerosis . 6 . History neuroleptic akathisia . 7 . Parenteral iron use within 6 week prior screen . 8 . History &gt; 10 blood transfusion past 2 year . 9 . Anticipated need blood transfusion study . 10 . Known hypersensitivity reaction component Injectafer® ( Ferric Carboxymaltose ) . 11 . Previously randomize Injectafer® ( FCM VIT45 ) clinical trial . 12 . Current , active acute chronic infection viral upper respiratory tract infection 13 . Malignancy ( basal squamous cell skin cancer subject cancer free ≥ 5 year ) . 14 . Pregnant lactating woman . 15 . Seizure disorder currently treat medication . 16 . Baseline ferritin ≥300 ng/mL . 17 . Baseline TSAT ≥45 % . 18 . History hemochromatosis , hemosiderosis , iron storage disorder . 19 . AST ALT great 2 time upper limit normal ( ULN ) . 20 . Hemoglobin great ULN . 21 . Known positive hepatitis B antigen ( HBsAg ) , unless positive test attribute receipt hepatitis B vaccination childhood hepatitis C viral antibody ( HCV ) evidence active hepatitis ( i.e. , AST/ALT great upper limit normal ) . 22 . Known positive HIV1/HIV2 antibody ( antiHIV ) . 23 . Received investigational drug within 30 day randomization . 24 . Chronic alcohol drug abuse within past 6 month . 25 . Any preexist laboratory abnormality , medical condition disease , per investigator may put subject risk participate study . 26 . Subject unable unwilling comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>